Eris Lifesciences has received approval from board of directors to execute Binding Term Sheet with Chemman Labs and selling shareholders of Chemman Labs for the purpose of acquiring 100% stake in Chemman Labs. The objective of acquisition is to create the capability and capacity for fill-finish of biological products including Insulins and its Analogues, GLP-1 agonists, rDNA products and a range of monoclonal antibodies. The said acquisition will be completed by September 30, 2024.
The Board of Directors of the Company, in their meeting held on August 02, 2024 has approved the same.
Eris Lifesciences develops, manufactures and commercializes branded pharmaceutical products in select therapeutic areas within the chronic and acute categories of the IPM, such as: cardiovascular; anti-diabetics; vitamins; gastroenterology; and anti-infectives.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1828.55 |
Dr. Reddys Lab | 1187.55 |
Cipla | 1556.35 |
Lupin | 2099.35 |
Zydus Lifesciences | 893.55 |
View more.. |